56632-39-4 Usage
Uses
Used in Anticancer Applications:
BHPI is used as an antagonist of estrogen receptor α (ERα) for blocking the proliferation of drug-resistant breast, endometrial, and ovarian cancer cell lines. It effectively inhibits 17β-estradiol-induced cell growth at concentrations ranging from 10 to 1,000 nM, both in vitro and in vivo. In mice bearing MCF-7 xenografts, BHPI drives tumor regression at a daily dose of 15 mg/kg. Additionally, it specifically suppresses ERα-dependent gene expression and protein synthesis by activating the unfolded protein response in cells.
Used in Pharmaceutical Industry:
BHPI is used as a potential therapeutic agent for the treatment of hormone-dependent cancers, such as breast, endometrial, and ovarian cancers. Its ability to inhibit the proliferation of drug-resistant cancer cells and its effectiveness in vivo make it a valuable compound for the development of novel cancer treatments and drug formulations.
Check Digit Verification of cas no
The CAS Registry Mumber 56632-39-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,6,6,3 and 2 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 56632-39:
(7*5)+(6*6)+(5*6)+(4*3)+(3*2)+(2*3)+(1*9)=134
134 % 10 = 4
So 56632-39-4 is a valid CAS Registry Number.
56632-39-4Relevant academic research and scientific papers
Syntheses and antiproliferative evaluation of oxyphenisatin derivatives
Uddin, Muhammed K.,Reignier, Serge G.,Coulter, Tom,Montalbetti, Christian,Granaes, Charlotta,Butcher, Steven,Krog-Jensen, Christian,Felding, Jakob
, p. 2854 - 2857 (2008/02/13)
Syntheses and structure-antiproliferative relationship for oxyphenisatin analogues are described. The cell proliferation data showed that the presence of substituents (especially F, Cl, Me, CF3, and OMe) in the 6- and 7-position of oxyphenisati
